IP Library Granted Patent US 8,039,006
Granted Patent B2
US 8,039,006 · App. 10/484,937 · Granted Oct 18, 2011

Solid composition containing bacillus-type non-pathogenic bacterial spores

Assignee: sanofi-aventis S.p.A.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,039,006
App. No.
10/484,937
Granted
Oct 18, 2011
Kind
B2
Abstract

The invention relates to a composition of spores of nonpathogenic bacteria of the Bacillus genus, adsorbed onto a matrix made up of at least one water-insoluble adsorbent compound and a cellulose derivative, which can be obtained by the fluidized air bed technique, useful in the pharmaceutical, veterinary and nutrition fields.

Claims (14)

1. A composition comprising live spores of nonpathogenic bacteria from one or more strains chosen from Bacillus clausii deposited in Collection Nationale De Cultures De Microorganisms of the Institute Pasteur assigned accession numbers I-273, I-274, I-275 and I-276, adsorbed onto a matrix made up of a water-insoluble adsorbent compound and a cellulose derivative obtained by mixing of a suspension of said live spores in an air-fluidized bed and a ratio by weight of said adsorbent compound to said cellulose derivative is between 90:10 and 10:90.

2. The composition according to claim 1 , obtained by treating a liquid suspension of said live spores with a matrix made up of at least one a water-insoluble adsorbent compound and a cellulose derivative.

3. The composition according to claim 1 containing from 3 to 30 billion of said live spores per gram of composition.

4. The composition according to claim 3 containing from 5 to 20 billion of said live spores per gram of composition.

5. The composition according to claim 4 containing approximately 10 billion of said live spores per gram of composition.

6. The composition according to claim 1 wherein said adsorbent compound is selected from kaolin and calcium carbonate.

7. The composition as according to claim 1 wherein said cellulose derivative is microcrystalline cellulose.

8. The composition according to claim 1 , wherein said ratio is between 70:30 and 30:70.

9. The composition according to claim 8 wherein said ratio is approximately 50:50.

10. The composition according to claim 1 in the form of a dosage unit in gel capsules or sachets.

11. The composition according to claim 10 , containing in each dosage unit from 1 to 10 billion live spores, from 50 to 500 mg of kaolin and from 50 to 600 mg of microcrystalline cellulose.

12. The composition according to claim 11 , containing in each dosage unit from 2 to 5 billion live spores, from 50 to 250 mg of kaolin and from 50 to 300 mg of microcrystalline cellulose.

13. The composition according to claim 10 , containing in each dosage unit approximately 2 billion live spores in gel capsules.

14. The composition according to claim 10 , containing in each dosage unit approximately 6 billion live spores in gel capsules.

Assignments (3)
CHANGE OF NAME Recorded Oct 11, 2010
From: SANOFI-SYNTHELABO OTC S.P.A.
To: SANOFI-AVENTIS OTC S.P.A.
Reel/Frame 025119/0667 →
MERGER Recorded Oct 11, 2010
From: SANOFI-AVENTIS OTC S.P.A.
To: SANOFI-AVENTIS S.P.A.
Reel/Frame 025119/0732 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2004
From: PRATO, TIZIANO
To: SANOFI-SYNTHELABO OTC SPA
Reel/Frame 015598/0177 →
Priority Claims (1)
IT 12001A001632 · Jul 27, 2001 · national
Continuity (1)
Related Publication 20040241772A1 · Dec 2, 2004